

References:

Asher, A., & Myers, J. S. (2015). The effect of cancer treatment on cognitive function. *Clinical Advances in Hematology & Oncology*, 13(7), 441-450.

Cimprich, Bernadine, Visovatti, Moira, & Ronis, David L. (2011). The Attention Function Index--a self-report cognitive measure. *Psycho-Oncology*, 20(2), 194-202. doi: 10.1002/pon.1729

Dutcher, Janice P., Schwartzenruber, Douglas J., Kaufman, Howard L., Agarwala, Sanjiv S., Tarhini, Ahmad A., Lowder, James N., & Atkins, Michael B. (2014). High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. *J Immunother Cancer*, 2(1), 1-23. doi: 10.1186/s40425-014-0026-0

Ejneary. (2011). Interleukin-2 Treatments for Stage 4 RCC: After first round.

Mann, T. K., Dail, R. B., & Bailey, D. E., Jr. (2015). Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy: An Integrative Literature Review. *Cancer Nursing*. doi: 10.1097/ncc.0000000000000317

Musselman, D., Royster, E. B., Wang, M., Long, Q., Trimble, L. M., Mann, T. K., . . . Miller, A. H. (2013). The Impact of Escitalopram on IL-2-Induced Neuroendocrine, Immune, and Behavioral Changes in Patients with Malignant Melanoma: Preliminary Findings. *Neuropsychopharmacology*, 38(10), 1921-1928. doi: 10.1038/npp.2013.85

Rossetti, H C, Lacritz, L H, Cullum, C M, & Weiner, M F. (2011). Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. *Neurology*, 27(77), 1272-1275.